University of Liverpool signs option agreement with BARD1 for type 3C diabetes test

The University of Liverpool has signed a two year option agreement with the Australian diagnostics company, BARD1 Life Sciences Ltd (ASX: BD1), for a type 3c diabetes (T3cDM) blood test. The test uses patented technology developed by researchers in the University of Liverpool’s Institute of Systems, Molecular and Integrative Biology.